A Study Of Therapeutic Potential Of RAAS Blocker Mediated Correction Of SGLT Activity In Diabetic Patient

Abstract

Diabetes mellitus is a group of chronic metabolic conditions which result from defective insulin secretion, insulin action or
both.In the type 1 and type 2 diabetes mellitus cardio-renal injury development are frequent.However,in diabetes pathology,
inhibition of SGLT1 results in an increase glucose homeostasis by decreasing dietary glucose absorption in the intestines.The
rise plasma renin function, median arterial pressure and renal vascular resistance, circulatory and local (intrarenal) activation of
RAAS, was linked to short-term mild hyperglycemia without glycosuria in early phases.The nicotinamide adenine dinucleotide
phosphate (NADPH) mediated generation of ROS via activation of Angiotensin II as a deleterious effect of RAAS in the event of
cardio-renal injury. Diabetes-related cardiovascular (CV) and renal complications can be attenuated by antihypertensive renin
angiotensin aldosterone system inhibitors (RAAS), especially by inhibitors of the angiotensin converting enzyme (ACE),
angiotensin receptor blockers (ARBs, etc.).An optimized concepts system for diabetes kidney pathogenesis and its relationship
with cardiovascular diseases would allow surveillance and pharmacotherapeutics to be developed to reduce the likelihood of
serious clinical cases and early deaths. Therefore, the aim of the study to explore the exact molecular insight of RAAS blocker
specifically ARBs in the prevention of diabetes and its cardio-renal injury.